Avidity Biosciences Gains FDA Orphan Drug Designation for Patients With DMD
Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).
United States Sarah Boyce Office Of Orphan Products Development Avidity Biosciences Image Credit American Journal
Source: ajmc.com